Abstract
A new acridone derivative, 2-aminoacetamido-10-(3, 5-dimethoxy)-benzyl-9(10H)-acridone hydrochloride (named 8a) synthesized in our lab shows potent antitumor activity, but the mechanism of action remains unclear. Herein, we report the use of an UPLC/Q-TOF MS metabolomic approach to study the effects of three compounds with structures optimized step-by-step, 9(10H)-acridone (A), 10-(3,5-dimethoxy)benzyl-9(10H)-acridone (I), and 8a, on CCRF-CEM leukemia cells and to shed new light on the probable antitumor mechanism of 8a. Acquired data were processed by principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) to identify potential biomarkers. Comparing 8a-treated CCRF-CEM leukemia cells with vehicle control (DMSO), 23 distinct metabolites involved in five metabolic pathways were identified. Metabolites from glutathione (GSH) and glycerophospholipid metabolism were investigated in detail, and results showed that GSH level and the reduced/oxidized glutathione (GSH/GSSG) ratio were significantly decreased in 8a-treated cells, while L-cysteinyl-glycine (L-Cys-Gly) and glutamate were greatly increased. In glycerophospholipid metabolism, cell membrane components phosphatidylcholines (PCs) were decreased in 8a-treated cells, while the oxidative products lysophosphatidylcholines (LPCs) were significantly increased. We further found that in 8a-treated cells, the reactive oxygen species (ROS) and lipid peroxidation product malondialdehyde (MDA) were notably increased, accompanied with decrease of mitochondrial transmembrane potential, release of cytochrome C and activation of caspase-3. Taken together our results suggest that the acridone derivative 8a induces oxidative stress-mediated apoptosis in CCRF-CEM leukemia cells. The UPLC/Q-TOF MS based metabolomic approach provides novel insights into the mechanistic studies of antitumor drugs from a point distinct from traditional biological investigations.
Introduction
Acridone derivatives with a unique molecular structure of two benzene rings fused together possess a wide range of biological activities, such as antivirus [1], anti-allergy [2], anti-malaria [3] and antitumor [4], [5], [6]. This feature is attributed to the semiplanar heterocyclic structure which appreciably interacts with different biomolecular targets. Acridone derivatives are found in natural plants [7]. However, the antitumor activity of acridone derivatives has attracted an increasing interest, and a large number of acridone derivatives have been chemically synthesized and tested for antitumor activity. These novel acridone derivatives act as DNA intercalators [8], [9], topoisomerase inhibitors [10], [11] or selective telomeric G-quadruplex DNA ligands [12], [13]. Antitumor activities of acridone derivatives have been traditionally characterized by molecular biological technologies [14], [15], [16], including MTT reduction assay for cellular proliferation, flow cytometry for cellular apoptosis, RT-PCR for gene expression, and Western blot for protein expression. The understanding of intensive antitumor mechanisms is limited because of the limitations of these conventional molecular biology approaches, such as poor repeatability, less quantity of data, and time-consuming and laboursome.
Metabolomics, a top-down systemic biology approach, provides insights into the global metabolic status of the entire organism through non-targeted analysis of metabolites in biological samples [17]. Moreover, metabolite alterations are not only sensitive to external stimuli and environmental factors but also respond to potential changes suggested by genomics and proteomics [18], [19]. Metabolomics has now been developed as a powerful tool for the disease diagnosis and monitoring [20], drug effect and toxicity evaluation [21], [22], biomarker identification [23], and food safety investigation [24], [25]. Therefore, metabolic profiling of cells underlying treatment with drug candidates is greatly helpful for understanding their action mechanisms and aids in their further modifications. Currently, the metabolomic-based technology has been reported for the exploration of drug-cell interactions [26], [27] and action mechanisms of drugs [28]. However, a comprehensive metabolite profile of acridone derivatives against cell lines is still lacking.
The metabolomic approach emphasizes on unbiased identification and quantification of low molecular weight metabolites (i.e. <1.5 kDa) present in biological samples, such as urine, plasma and cell extracts. Different analytical techniques have been used for metabolomic study, including gas chromatography-mass spectrometry (GC-MS) [29], liquid chromatography-mass spectrometry (LC-MS) [30] and nuclear magnetic resonance (NMR) [31]. Chemometric and mathematical modeling methods, such as principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA), are used to interpret the acquired complex data. Compared with LC-MS, ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UPLC-MS) offers several advantages, such as better chromatographic peak resolution, shorter analysis time and higher sensitivity, and thus is more appropriate for the metabolomic analysis.
In our previous studies, a series of acridone derivatives have been synthesized, and among them, the derivative 8a, 2-aminoacetamido-10-(3,5-dimethoxy)-benzyl-9(10H)-acridone hydrochloride (Figure 1A), has shown potent antitumor activity. However, the underlying mechanism of the anti-proliferative activity of 8a is unclear [32]. This current study presented a global analysis of metabolic changes in CCRF-CEM leukemia cells treated with 9(10H)-acridone (A), 10-(3,5-dimethoxy)benzyl-9(10H)-acridone (I), and 8a (the optimized structure based on the former two compounds). Distinct metabolites were identified and the involved biological events were verified by conventional molecular biology.
Experiments
Chemicals and Reagents
Compound 8a and I synthesized by our lab [33] and A (Sigma-Aldrich Co., USA) were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co., USA) with final concentration of 10 mM as stock solutions. Acetonitrile and methanol (HPLC grade) were purchased from Fisher (Fairlawn, USA). HPLC grade formic acid was purchased from Tedia (Tedia Co., USA). Distilled water was filtered through a Milli-Q system (Millipore, USA). RPMI 1640 was purchased from Invitrogen (Grand Island, USA). Fetal bovine serum (FBS) was purchased from Hyclone (Logan, USA). Streptomycin sulfate and penicillin were purchased from North China Pharmaceutical, China.
Sample Preparation for Metabolomics
CCRF-CEM leukemia cells (Human T cell lymphoblast-like cell line) were obtained from the Chinese Academy of Sciences Cell Bank. The cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 µg/mL penicillin, and 100 µg/mL streptomycin. Cells were maintained at 37°C in an atmosphere of 5% CO2 incubator with the medium replaced every 24 h. 1×107 cells in a 10 cm dish were exposed to 0.5 µM of 8a, I or A or an equal amount of DMSO as a control. Eight replicates in separate dishes for each group were analyzed. The final concentration of DMSO was less than 0.1%. After 24 h incubation, cells were centrifuged at 300 g for 5 min at room temperature and harvested. The cell numbers were then counted with hemacytometer and used for normalization of the metabolite levels. The cell pellets were subsequently gentle resuspended in 1.0 mL ice cold isotonic saline (0.9% [w/v] NaCl) [34]. As reported in the literature, the cold isotonic saline did no damage cells and could effectively arrest cellular metabolism. The cells were then centrifuged at 1000 g for 1 min, and the isotonic saline solution was aspirated. The cell pellets were then immediately dissolved in 1.0 mL mixture of methanol/water in ratio of 4∶1 (v/v) at –20°C [35]. Then the cells were ultrasonicated in an ice bath ultra-sonicator for 10 min and subsequently centrifuged at 13000 g for 10 min at 4°C. The supernatant was collected and dried with a stream of nitrogen. The residues were resuspended in 1.0 mL acetonitrile/water (1∶1, v/v) mix, and were filtered through 0.22 µm mesh millipore filters (Florham Park, NJ) into glass auto-samplers. The samples were stored at –80°C prior to analysis. In parallel a quality control (QC) sample was prepared by mixing equal volumes of 30 µL into a glass auto-sampler from each of the 32 samples. The pooled QC samples were injected five times at the beginning and of the run in order to condition or equilibrate the system and then analyzed every three samples to further monitor the stability of the analysis.
UPLC/Q-TOF MS Conditions
UPLC/Q-TOF MS analysis was performed using Acquity™ Ultra-Performance Liquid Chromatography system (Waters Corporation, MA, USA) coupled to Q-TOF premier Mass Spectrometer (Waters Corporation, MA, USA). The chromatographic separation was carried out on a Waters Acquity™ BEH C18 column (100 mm×2.1 mm, 1.7 µm). The column and samples were maintained at temperatures of 35°C and 4°C, respectively. The flow rate was at 0.5 mL/min. The mobile phase consisted of (A) 0.1% formic acid in water and (B) acetonitrile in positive mode, while (A1) 5 mM ammonium acetate in water and (B1) 5 mM ammonium acetate in acetonitrile (95∶5, v/v) in negative mode. Elution gradient was linearly increased from 5% to 40% B (B1) within 5 min, then to 100% B (B1) within 5 min and held for 1 min, followed by return to 5% B. Total running time was 14 min per separation. A 10 µL sample volume was introduced onto the column. The Waters Q-TOF premier equipped with an electrospray ion source in both positive and negative ion electrospray (ESI+ and ESI−) modes and V optics mode. The capillary voltage was 3.0 kV (ESI+) and 2.5 kV (ESI−), cone voltage was 35V (ESI+) and 30 V (ESI−). Cone gas flow was set at 50 L/hr with source temperature of 120°C. Desolvation gas flow was maintained at 550 L/hr with the desolvation gas temperature of 300°C. Data were collected in the centroid mode. The mass range was m/z 100–1000 with a scan time of 0.15 s and interscan time 0.02 s. For mass accuracy a LockSpray™ interface was used with Leucine-enkephalin (m/z 556.2771, ESI+; m/z 554.2615, ESI−) at a final concentration of 100 pg/uL in acetonitrile-water with 0.1% formic acid (50∶50 v/v) was used as the lock mass (m/z 556.2771) with a flow rate of 0.05 mL/min. Lock spray frequency was set at 10 s and scan to average for correction was 10 s with the reference cone voltage at 35 V. For MS/MS analysis, the collision energies were set in ramp mode ranged from 10 V to 30 V.
Multivariate Data Analysis
Original data was processed using the MarkerLynx software (version 4.1, Waters Corporation, MA, USA) which used Apex-Track-peak detection package to integrate peaks in UPLC/MS data. Peaks in each chromatogram were identified by m/z, retention time (RT) as well as their associated height intensities. The three-dimensional data, peak number (RT_m/z pair), sample name, and normalized ion intensity were introduced to SIMCA-P 11.5 software package (Umetrics, Umea, Sweden) for multivariate data analysis. The variables were transformed by mean-centering and Pareto scaling to increase the low abundance ions without significant amplification of noise, and then analyzed by PCA and OPLS-DA. PCA is an unsupervised multivariate statistical approach. It is used for variable reduction and separation into classes. To maximize class discrimination and biomarkers, the data were further analyzed using the OPLS-DA method [36]. In this study, the control and 8a-treated groups were compared in the OPLS-DA method. S-plots were calculated to visualize the relationship between covariance and correlation within the OPLS-DA results. Variables that had significant contributions to discrimination between groups were considered as potential biomarkers and subjected to further identification of the molecular formula. Databases of HMDB (http://www.hmdb.ca/) and METLIN (http://metlin.scripps.edu/) were used to identify the metabolite markers with tandem mass spectrometry. Standards of metabolic interest were used to confirm their structures.
Cell Viability and Flow Cytometric Assays
CCRF-CEM cells were suspended at a concentration of 2×105 cells/mL and seeded in 96-well microtiter plates. 0.2, 0.5, and 1 µM of 8a were added to each well in sextuplet and then incubated for 8 h, 16 h, 24 h, and 32 h respectively. After treatment, the cells were incubated with 10 µL of MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide from Sigma) solution (5 mg/mL) for 4 h. The formazan precipitate was dissolved in 100 µL DMSO and the absorbance at 490 nm was measured by a Benchmark microplate reader (Molecular Devices Corporation, USA). The apoptotic cells were measured by the Annexin V-FITC/PI apoptosis detection kit (Beyotime Institute of Biotechnology, China) according to the protocol described using flow cytometry (Moflo XDP, Beckman Coulter, USA). Briefly, CCRF-CEM cells were exposed to 0.5 µM 8a for 24 h at 37°C. Then cells were collected by centrifugation and washed twice with ice-cold phosphate-buffered saline (PBS). Positive Annexin V staining indicated apoptosis, while positive PI indicated necrosis. For each group, a minimum of 10,000 cells were used.
Detection of Reactive Oxygen Species (ROS) Level and Mitochondrial Transmembrane Potential (MMP)
The levels of intracellular ROS and MMP were determined according to their described protocol respectively. Cells were treated with 0.5, 1, 2 µM of 8a, harvested, and suspended in PBS. 1×106 cells were separately incubated with 10 µM 2′, 7′-dichlorfluorescein-diacetate (DCFH-DA) and 2 µM Rh123 in dark for 30 min at 37°C for ROS and MMP detection. The fluorescence was detected with a fluorescence spectrophotometer (ROS, 485 nm Ex and 525 nm Em; MMP, 507 nm Ex and 529 nm Em).
Determination of Lipid Peroxidation
Malondialdehyde (MDA), an indicator of lipid peroxidation was quantified by a Lipid Peroxidation MDA assay kit (Beyotime Institute of Biotechnology, China) according to the manufacturer’s protocol. In brief, cells were treated with 0.5, 1, 2 µM of 8a. They were centrifuged and sonicated in 100 µL of lysis buffer (10 mM Hepes pH 7.9, 10 mM KCl, 1 mM EDTA, 0.1% NP-40, 1 mM Na3VO4, 1 mM DTT) combined with proteinase inhibitor cocktail (Thermo Scientific, USA). After sonication, lysed cells were centrifuged at 10000 g for 10 min to remove debris. The supernatant was subjected to the measurement of malondialdehyde (MDA) levels and the protein contents. 100 µL of 0.09% Thiobarbituric acid (TBA) containing antioxidant was added to the supernatant to react with MDA. This mixture was incubated at 100°C for 15 min. Thiobarbituric acid reactive species (TBARS) produced were measured at 532 nm using Varioskan Flash Multimode Reader (Thermo Scientific, USA) and the absorbance was compared with that of standard curve using MDA. Protein concentrations were determined by BCA kit (Bio Tec Inc, USA) using a multi-function detector (Beckman, German). MDA levels were then normalized to milligram protein. The extraction and quantification of proteins were determined used the same procedure in the following assays unless otherwise indicated.
Mitochondrial and Cytosolic Fractionation
Prior to determine the release of cytochrome C from mitochondria to cytosol, the isolation of mitochondria and cytosol was performed using the Cell Mitochondria Isolation Kit (Beyotime Institute of Biotechnology, China). Briefly, 5×107 cells were treated with 0.5 µM of 8a and harvested. They were then incubated in 100 µL ice-cold mitochondrial lysis buffer on ice for 10 min. Cell suspension was then taken into a glass homogenizer and homogenized for 50 strokes using a tight pestle on ice. The homogenate was then centrifuged at 600 g for 10 min at 4°C to remove nuclei and unbroken cells. Then the supernatant was collected and centrifuged again at 12000 g for 15 min at 4°C to obtain the mitochondria (deposition) and cytosol (supernatant) fractions. Samples of mitochondria and cytosol were dissolved in lysis buffer and proteins were subjected to Western blotting, respectively.
Western Blotting Analysis
Cells were treated with 0.5, 1 µM of 8a and harvested. Proteins were extracted from the cells, separated in 15% SDS-polyacrylamide gel, and then transferred to PVDF membranes. The membranes were blocked in TBST buffer (0.125 M NaCl,25 mM Tris pH 8.0) containing 5% defatted milk for 1 h and then incubated with specific first antibody overnight at 4°C. Protein bands were detected using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, USA) after hybridization with horseradish peroxidase-conjugated second antibody. Procaspase-3 and cleaved caspase-3 antibodies (Cell Signaling Technologies, 9662) were the first antibodies for caspase detection, while anticytochrome C antibody (Abcam, ab76237) was for cytochrome C assay.
Statistical Analysis
For metabolomic experiments, eight independent biological samples from separated dishes for each group were performed. While the biological experiments for the biological events verification were repeated at least three times. Data are expressed as means ± standard deviation (SD). Student’s t-test was used to determine the significances of differences in multiple comparisons. Values of p<0.05 were considered statistically significant.
Results and Discussion
Anti-proliferative Activity of Acridone Derivatives
Parental compound A had no cytotoxicity (IC50>100 µM), but the derivative compound I with dimethoxy groups on the benzene ring of A showed appreciable cell growth inhibition. Interestingly, the new derivative compound 8a with terminal amino substituents at C2 position on the acridone ring of I exhibited the most potent anti-proliferative activity with an IC50 at 0.39 µM (Table S1). Structure–activity analysis indicated that both the acridone group and substituted groups on the parental compound affected the cytotoxicity of acridone derivatives.
The non-targeted metabolomic approach as an emerging tool in cancer research was conducted in an unbiased manner. Prior to metabolomic analysis, the effects of compound concentrations and incubation time on CCRF-CEM cell viability were investigated to obtain the optimal cellular activity with minimal cell death. Among the tested compounds A, I and 8a, the 8a possessed the most significant anti-proliferative activity and thus was chosen to test the optimal concentrations and treatment time. As shown in Figure 1B, incubation time ranging from 8 to 32 hours did not significantly affect the cytotoxicity of 8a, but its antiproliferative activity increased significantly with increase of the concentrations. At 0.2 µM, 8a was not significantly toxic to CCRF-CEM cells, but led to more than 40% decrease of viable cells when its concentration was increased to 1.0 µM. When 8a was used at 0.5 µM for 24 h, the viability of CCRF-CEM cells was at approximately 80%. Flow cytometry assay confirmed this MTT result that at 0.5 µM for 24 h, 8a led to 16.27% apoptotic cell death (Figure 1C). This treatment condition was used for the following experiments.
Metabolomic Analysis of Compounds 8a, I and A-treated Cells
To investigate the metabolic fingerprints in cancer cells, metabolites in CCRF-CEM cells from control and treated groups were profiled by UPLC/Q-TOF MS in both positive and negative modes, though positive ion mode gave more information-rich data than negative. Representative base peak intensity (BPI) chromatograms were shown in Figure S1. Raw data from UPLC/Q-TOF MS were analyzed by the Marker-Lynx software. The acquired QC data for UPLC/Q-TOF MS metabolic profiling were used to investigate the analytical variability in the whole run, which was critical for evaluating the variations in the analytical results and thus the reliability of the metabolite profiling data [37]. As shown in Figure 2A, the QC samples were tightly clustered in PCA scores plot, indicating the non-targeted analysis displayed the column stability in the whole run. Moreover, it was noteworthy that the control and 8a-treated groups were obviously separated along the first principal component, while A and I treated groups were not significantly different from the control group. It is indicated that the cellular metabolic phenotypes were significantly altered under the treatment of 8a. The results were in agreement with aforementioned anti-proliferative activity.
Feature selection was conducted using OPLS-DA for these two groups of cells to depict the metabolic signature. As shown in Figure 2B, the score plots of OPLS-DA between the control and 8a groups were clearly separated. R2Y (cum), the fraction of the variation of Y (all the responses) explained by the model after each component, and Q2 (cum), the fraction of the variation of Y that can be predicted by the model according to cross-validations, were used to evaluate the OPLS-DA model. The R2Y (cum) and Q2 (cum) were 0.761 and 0.433, respectively. These results suggest that the model explains 76.1% of the variations of Y, with a predictive ability (Q2) of 43.3%. The S-plot is a scatter plot which combines the covariance and correlation loading profiles arising from the predictive components of the OPLS-DA model. We carried out this analysis to visualize variables that have significant contributions to the discrimination of these two groups. The significant variables, with high correlation and covariance values, were located in regions far away from the origin (red boxes in Figure 2C), and were selected as potential biomarkers. An independent t-test indicated that these variables between the control and 8a-treated cells were statistically significant (p<0.05).
Identification of Metabolic Biomarkers
Metabolite identification was conducted with high resolution MS and MS/MS fragments, as well as database analysis. The authentic metabolite standards of interest, as available, were used for confirmation in both m/z and RT. Lipids were tentatively identified by high mass accuracy and MS/MS fragment ions without authentic standards comparison [20], [38].
On the basis of UPLC/Q-TOF MS metabolomics, identified variables from comparisons (8a, I or A-treated groups vs. control group, respectively) were summarized in Table S2, including RT, the mass obtained in UPLC-MS system, and the mass error when comparing with the database. In addition, the type of the identification (MS/MS fragmentation or confirmation with the analysis of standard), fragment ions of the metabolite, percentage of changes in different comparisons, and statistical significance were also presented in the table. It is shown that the metabolites in 8a-treated group were the most significantly changed. By comparing the 8a-treated group with the control, 23 metabolites were highlighted, which were derived from altered fatty acid, nucleoside, amino acid, glycerophospholipid, and glutathione metabolism. Further studies were focused on 11 metabolites which were involved in glutathione and glycerophospholipid metabolism. As shown in Figure 3, the metabolites in 8a, I and A-treated groups showed the same variation tendency, but extents of the changes in 8a-treated group were significantly larger than the other two groups. Therefore, the analysis of the changed metabolites, as well as the following biological studies, were focused on 8a-treated group.
Metabolites produced in glutathione metabolism include reduced glutathione (GSH), oxidized glutathione (GSSG), L-cysteinyl-glycine (L-Cys-Gly), glutamate, and pyroglutamic acid. GSH, containing an important functional thiol group, is a major endogenous antioxidant and plays a key role in eliminating the free radicals and ROS, as well as reducing oxidized or inactivated protein thiols in order to ensure their biological activities. Therefore, GSH is considered as an important indicator of oxidative stress [39], [40]. As shown in Figure 3A, the reduced GSH was decreased by nearly 70% in 8a-treated cells compared to the vehicle control (8a/control = 0.304±0.161, p<0.05), suggesting oxidative stress induced by the acridone derivative 8a. This phenomenon is in accordance with the intoxication condition caused by toxins [41]. Interestingly, the metabolites of GSH, L-Cys-Gly and glutamate, were increased by 80% in the cells treated by 8a (p<0.05), suggesting that GSH was also exhausted by increased metabolic degradation. Nevertheless, these results indicate that the novel acridone derivative 8a may induce GSH deficiency and oxidative stress as a primary mechanism for its antitumor activity (see below).
We further investigated glycerophospholipid metabolites with a focus on lysophosphatidylcholines (LPCs) and phosphatidylcholines (PCs) (Figure 3B). Compared to the control, three LPCs, including LysoPC (18∶0), LysoPC (18∶1) and LysoPC (20∶3), were increased by 2.88 times or more in 8a-treated cells. It has been reported that LPCs are produced as oxidation at the sn-2 fatty acids by ROS [42]. These results were consistent with above observations that 8a induced oxidative stress and led to lipid peroxidation. On the contrary, 5 PCs were significantly decreased (p<0.05) in 8a-treated cells, including three saturated fatty acid PCs [PC (13∶0/0∶0), PC (15∶0/0∶0) and PC (16∶0/0∶0)] and two unsaturated fatty acid PC [PC (12∶1/24∶3) and PC (16∶0/22∶6)]. These PCs are the main lipid components of biomembranes, and their decrease indicates the lesions of cell membranes induced by 8a [43].
Metabolites Stability Evaluation
Stability of metabolites is a major concern on the data accuracy of metabolomic studies due to the time-consuming in sample analysis (10–30 min per sample). The stability of metabolites may be influenced by enzymatic action, degradation of macromolecules to release metabolites, and inherent chemical lability. In order to evaluate the metabolites stability, samples were reanalyzed three times with 10 h interval at 4°C to mimic typical autosampler storage. The metabolites peak areas were compared with initial values. As shown in Table S3, the relative standard deviative (RSD) in three independent experiments were less than 7%. These results demonstrated the metabolites tested, including GSH and GSSG, showed excellent stability in the experimental conditions.
Oxidative Stress and Mitochondrial Lesions Induced by 8a
We further investigated the cellular ROS level and mitochondrial function to prove the oxidative stress and cell death triggered by 8a. The 8a-induced intercellular ROS generation was measured using a permeable fluorescence probe, DCFH-DA, which is oxidized to generate fluorescent DCF in the presence of ROS [44]. DCF fluorescence was detected after cells were exposed to 0.5–2 µM 8a for 24 h. The results showed that the intracellular ROS was significantly increased in a dose-dependent manner (p<0.05) (Figure 4A). ROS causes injuries to biomolecules, such as nucleic acids, proteins, structural carbohydrates, and lipids. The peroxidation of lipids by ROS is one of the major injuries to cells. To prove the lipid peroxidation induced by 8a, we tested the cellular MDA levels, a by-product of lipid peroxidation [45]. As shown in Figure 4B, the MDA level was increased by 1.4-fold in the cells treated with 0.5 µM 8a for 24 h, demonstrating a similar tendency to the cellular ROS level. Taking these data together with our aforementioned metabolomic results, it is conclusive that 8a triggers oxidative stress and subsequent lipid peroxidation in the CCRF-CEM cells, leading to the changes of metabolites of GSH and phospholipids.
Mitochondria are an important organelle for cell survival and a vulnerable target of ROS. MMP is important to the integrity and function of mitochondria [46], [47]. To understand the cell death mechanism, we further evaluated MMP in 8a-treated cells using a fluorescent dye Rh123, a cell permeable cationic dye which can specifically binds to the active mitochondria based on the highly negative MMP. As shown in Figure 5A, treatment with 0.5–2 µM 8a for 24 h led to drastic decrease of MMP in a dose-dependent manner. When CCRF-CEM cells were exposed to 0.5, 1.0, and 2.0 µM of 8a, the fold changes of MMP to control cells, calculated from the mean MMP of all tested cells, were 0.837±0.039, 0.556±0.029, and 0.279±0.027, respectively.
Intrinsic apoptosis is initiated by a mitochondrial-mediated pathway, including the alteration of MMP, the release of cytochrome C into cytosol, and the activation of caspase-3 [48]. Therefore, we further examined the mitochondrial cytochrome C release. After cells were treated with 8a at 0.5 µM for 24 h, mitochondrial cytochrome C was significantly reduced, accompanied with the increase in cytosol, indicating enhanced cytochrome C release in these cells (Figure 5B). After the reduction of MMP and the release of mitochondrial cytochrome C, a critical step is the formation of apoptosomes, which ultimately cleave procaspase-3 to form active caspase-3. Caspases play critical roles in the execution of apoptosis [49]. Western blot analysis indicated that dramatic caspase-3 was activated in 8a-induced CCRF-CEM cells (Figure 5C). All together, these results suggest a mitochondrial-mediated cell apoptosis pathway is activated by 8a.
Conclusions
In this study, an UPLC/Q-TOF MS based metabolomic method was established to investigate the metabolite changes of two acridone derivatives (I and 8a) and their parental compound A in CCRF-CEM cells in order to predict hypothetic antitumor mechanism of 8a in CCRF-CEM cells. Results revealed that 8a possessed the strongest anti-proliferative activity and the most significant discrimination in the cell metabolic phenotypes compared with vehicle control group. Comparing 8a with the control group, twenty three distinct metabolites involved in five metabolic pathways were identified. Two metabolic pathways, i.e., glutathione and glycerophospholipid metabolism were investigated in depth to understand the cell death mechanism induced by 8a; 11 metabolites were identified as biomarkers for antitumor activity. Biological studies were further conducted to confirm the underlying cellular events. Combining the metabolomic and biological results, we propose a schematic hypothesis for the anti-proliferative mechanism of 8a (Figure 6). In CCRF-CEM cells, 8a provokes oxidative stress, which in turn leads to lipid peroxidation and mitochondrial lesions and potential changes. Cytochrome C release resulting from mitochondrial potential changes then triggers caspase-3 mediated apoptosis. These findings enhance our understanding of the action mechanisms of 8a anti-proliferation and aid in their incorporation into further improvement.
Supporting Information
Acknowledgments
We would like to thank Dr. Shuhai Lin for his helpful suggestions on article writing. We appreciate Qinsheng Sun for his technical help with cell culture.
Funding Statement
The research work was supported in part by the Chinese National Natural Science Foundation of China (Nos. 21172129), a finance supported by Chinese National Natural Science Foundation of China (20902053), China Postdoctoral Science Foundation (number 2012M510407), China Ministry of Science and Technology under Contract (number 2012ZX09506001-010), and International S&T Cooperation Program of China (number 2011DFA30620). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Stankiewicz-Drogon A, Dorner B, Erker T, Boguszewska-Chachulska AM (2010) Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. J Med Chem 53: 3117–3126. [DOI] [PubMed] [Google Scholar]
- 2. Chukaew A, Ponglimanont C, Karalai C, Tewtrakul S (2008) Potential anti-allergic acridone alkaloids from the roots of Atalantia monophylla . Phytochemistry 69: 2616–2620. [DOI] [PubMed] [Google Scholar]
- 3. Valdés AFC (2011) Acridine and Acridinones: Old and New Structures with Antimalarial Activity. The open Med Chem J 5: 11–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Cholewinski G, Dzierzbicka K, Kolodziejczyk AM (2011) Natural and synthetic acridines/acridones as antitumor agents: their biological activities and methods of synthesis. Pharmacol Rep 63: 305–336. [DOI] [PubMed] [Google Scholar]
- 5. Koba M, Baczek T (2011) Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies. Med Chem Res 20: 1385–1393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Rajendra Prasad V, Peters G, Lemos C, Kathmann I, Mayur Y (2011) Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies. Eur J Pharm Sci 43: 217–224. [DOI] [PubMed] [Google Scholar]
- 7. Michael JP (1997) Quinoline, quinazoline and acridone alkaloids. Nat Prod Rep 22: 627–646. [DOI] [PubMed] [Google Scholar]
- 8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185–229. [DOI] [PubMed] [Google Scholar]
- 9. Baguley BC, Wakelin LP, Jacintho JD, Kovacic P (2003) Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? Curr Med Chem 10: 2643–2649. [DOI] [PubMed] [Google Scholar]
- 10. Raza A, Jacobson BA, Benoit A, Patel MR, Jay-Dixon J, et al. (2012) Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Invest New Drugs 30: 1443–1448. [DOI] [PubMed] [Google Scholar]
- 11. Salimon J, Salih N, Yousif E, Hameed A, Kreem A (2010) Synthesis and pharmacological evaluation of 9 (10H)-acridone bearing 1, 3, 4-oxadiazole derivatives as antimicrobial agents. Arab J Chem 3: 205–210. [Google Scholar]
- 12. Gao C, Li S, Lang X, Liu H, Liu F, et al. (2012) Synthesis and evaluation of l0-(3, 5-dimethoxy) benzyl-9 (10H)-acridone derivatives as selective telomeric G-quadruplex DNA ligands. Tetrahedron 68: 7920–7925. [Google Scholar]
- 13. Cuenca F, Moore MJB, Johnson K, Guyen B, De Cian A, et al. (2009) Design, synthesis and evaluation of 4, 5-di-substituted acridone ligands with high G-quadruplex affinity and selectivity, together with low toxicity to normal cells. Bioorg Med Chem Lett 19: 5109–5113. [DOI] [PubMed] [Google Scholar]
- 14. Su TL, Huang HM, Wang CK, Wu HC, Lin CT (2005) Cytochrome C release induces apoptosis of nasopharyngeal carcinoma (NPC) by antitumor glyfoline. Planta Med 71: 28–32. [DOI] [PubMed] [Google Scholar]
- 15. Fernández-Calienes A, Pellón R, Docampo M, Fascio M, D’Accorso N, et al. (2011) Antimalarial activity of new acridinone derivatives. Biomed Pharmacother 65: 210–214. [DOI] [PubMed] [Google Scholar]
- 16. Roseghini R, Falcão GM, Oliveira Costa JF, Clarêncio J, Nascimento I, et al. (2009) The flavonoid rutin but not the alkaloid arborinine induces apoptosis in a B-cell hybridoma cell line. Planta Med 75: 488–493. [DOI] [PubMed] [Google Scholar]
- 17. Nicholson JK, Lindon JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181–1189. [DOI] [PubMed] [Google Scholar]
- 18. Bundy JG, Iyer NG, Gentile MS, Hu DE, Kettunen M, et al. (2006) Metabolic consequences of p300 gene deletion in human colon cancer cells. Cancer Res 66: 7606–7614. [DOI] [PubMed] [Google Scholar]
- 19. Blaise BJ, Giacomotto J, Elena B, Dumas ME, Toulhoat P, et al. (2007) Metabotyping of Caenorhabditis elegans reveals latent phenotypes. Proc Natl Acad Sci USA 104: 19808–19812. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Li S, Liu H, Jin Y, Lin S, Cai Z, et al. (2011) Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2369–2375. [DOI] [PubMed] [Google Scholar]
- 21. Griffin JL (2004) The potential of metabonomics in drug safety and toxicology. Drug Discov Today Tech 1: 285–293. [DOI] [PubMed] [Google Scholar]
- 22. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1: 153–162. [DOI] [PubMed] [Google Scholar]
- 23. Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, et al. (2007) Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 3: 413–426. [Google Scholar]
- 24. Kuiper HA, Kok EJ, Engel KH (2003) Exploitation of molecular profiling techniques for GM food safety assessment. Curr Opin Biotechnol 14: 238–243. [DOI] [PubMed] [Google Scholar]
- 25. Wishart DS (2008) Metabolomics: applications to food science and nutrition research. Trends Food Sci Technol 19: 482–493. [Google Scholar]
- 26. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PloS one 4: e4251. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Wang M, Bai J, Chen WN, Ching CB (2010) Metabolomic Profiling of Cellular Responses to Carvedilol Enantiomers in Vascular Smooth Muscle Cells. PloS one 5: e15441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, et al. (2012) Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. Science 336: 1040–1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Lin S, Liu N, Yang Z, Song W, Wang P, et al. (2010) GC/MS-based metabolomics reveals fatty acid biosynthesis and cholesterol metabolism in cell lines infected with influenza A virus. Talanta 83: 262–268. [DOI] [PubMed] [Google Scholar]
- 30. Lin S, Chan W, Li J, Cai Z (2010) Liquid chromatography/mass spectrometry for investigating the biochemical effects induced by aristolochic acid in rats: the plasma metabolome. Rapid Commun Mass Spectrom 24: 1312–1318. [DOI] [PubMed] [Google Scholar]
- 31. Moolenaar S, Engelke U, Wevers R (2003) Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann Clin Biochem 40: 16–24. [DOI] [PubMed] [Google Scholar]
- 32. Gao C, Liu F, Luan X, Tan C, Liu H, et al. (2010) Novel synthetic 2-amino-10-(3, 5-dimethoxy) benzyl-9 (10H)-acridinone derivatives as potent DNA-binding antiproliferative agents. Bioorg Med Chem 18: 7507–7514. [DOI] [PubMed] [Google Scholar]
- 33. Gao C, Jiang Y, Tan C, Zu X, Liu H, et al. (2008) Synthesis and potent antileukemic activities of 10-benzyl-9(10H)-acridinones. Bioorg Med Chem 16: 8670–8675. [DOI] [PubMed] [Google Scholar]
- 34. Dietmair S, Timmins NE, Gray PP, Nielsen LK, Kromer JO (2010) Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal Biochem 404: 155–164. [DOI] [PubMed] [Google Scholar]
- 35. Sellick CA, Knight D, Croxford AS, Maqsood AR, Stephens GM, et al. (2010) Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells: matching extraction approaches to cell type and metabolite targets. Metabolomics 6: 427–438. [Google Scholar]
- 36. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometr 20: 341–351. [Google Scholar]
- 37. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, et al. (2010) Global metabolic profiling procedures for urine using UPLC–MS. Nat Protoc 5: 1005–1018. [DOI] [PubMed] [Google Scholar]
- 38. Cai S, Huo T, Li N, Xiong Z, Li F (2009) Lysophosphatidylcholine–biomarker of metformin action: studied using UPLC/MS/MS. Biomed Chromatogr 23: 782–786. [DOI] [PubMed] [Google Scholar]
- 39. Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R (2003) An improved HPLC measurement for GSH and GSSG in human blood. Free Radic Biol Med 35: 1365–1372. [DOI] [PubMed] [Google Scholar]
- 40. Scholz R, Graham K, Gumpricht E, Reddy C (1989) Mechanism of interaction of vitamin E and glutathione in the protection against membrane lipid peroxidation. Ann NY Acad Sci 570: 514–517. [Google Scholar]
- 41. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, et al. (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231–234. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 42. Catalá A (2009) Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids 157: 1–11. [DOI] [PubMed] [Google Scholar]
- 43. Wright MM, Howe AG, Zaremberg V (2004) Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem Cell Biol 82: 18–26. [DOI] [PubMed] [Google Scholar]
- 44. Wang C, Yan R, Luo D, Watabe K, Liao DF, et al. (2009) Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 284: 26742–26748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Yan R, Zu X, Ma J, Liu Z, Adeyanju M, et al. (2007) Aldo–keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 121: 2301–2306. [DOI] [PubMed] [Google Scholar]
- 46. Indran IR, Hande MP, Pervaiz S (2011) hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res 71: 266–276. [DOI] [PubMed] [Google Scholar]
- 47. Yan C, Huang D, Zhang Y (2011) The involvement of ROS overproduction and mitochondrial dysfunction in PBDE-47-induced apoptosis on Jurkat cells. Exp Toxicol Pathol 63: 413–417. [DOI] [PubMed] [Google Scholar]
- 48. Jin S, Zhang Q, Kang X, Wang J, Zhao W (2010) Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann Oncol 21: 263–268. [DOI] [PubMed] [Google Scholar]
- 49. Spencer SL, Sorger PK (2011) Measuring and modeling apoptosis in single cells. Cell 144: 926–939. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.